Imunins

Imunins is a Spanish biotechnology company specializing in the development of innovative therapies based on the use of mesenchymal stromal cells (MSCs). Founded in 2009, the company is headquartered in Madrid and focuses on regenerative medicine, particularly for autoimmune diseases and other conditions where immune modulation is beneficial.

The core technology of Imunins revolves around the therapeutic potential of MSCs, which are multipotent cells capable of differentiating into various cell types and possessing strong immunomodulatory properties. These cells are derived from sources such as bone marrow, adipose tissue, or umbilical cord blood. Imunins’ approach leverages MSCs to restore immune balance, reduce inflammation, and promote tissue repair.

One of Imunins’ key products is **IMU-131**, an allogeneic (donor-derived) MSC-based therapy designed for the treatment of graft-versus-host disease (GVHD), a severe complication following hematopoietic stem cell transplantation. The company has also explored applications in other autoimmune disorders, such as systemic lupus erythematosus and multiple sclerosis, though these remain in early-stage research.

Imunins has collaborated with academic institutions and research centers to advance its clinical programs. The company has conducted several clinical trials, including Phase I/II studies for GVHD, demonstrating safety and preliminary efficacy. In 2021, Imunins announced a strategic partnership with a major pharmaceutical company to accelerate the development of its lead product.

Beyond therapeutic development, Imunins contributes to scientific knowledge through research on MSC mechanisms, including their role in immune regulation and tissue regeneration. The company emphasizes personalized medicine approaches, aiming to tailor MSC therapies to individual patient needs.

Imunins operates under regulatory oversight, adhering to international standards for cell-based therapies. Its mission is to translate cutting-edge regenerative medicine into clinically viable treatments, ultimately improving patient outcomes in conditions where conventional therapies are limited.